Table 3 Bivariate analyses between clusters SV1, SV2, and SV3 upon SEB stimulation and clinical and biological parameters.

From: Deciphering heterogeneity of septic shock patients using immune functional assays: a proof of concept study

 

Cluster SV1 (n = 11)

Cluster SV2 (n = 14)

Cluster SV3 (n = 15)

p value

Status

   

< 0.001

Healthy, n (%)

10 (91)

0 (0)

0 (0)

 

Sepsis patients, n (%)

0 (0)

6 (43)

4 (27)

 

Septic shock patients, n (%)

1 (8)

8 (57)

11 (73)

 

Comorbidities*,a

   

0.427

No, n (%)

0 (0)

5 (35.7)

3 (20)

 

Yes, n (%)

1 (100)

9 (64.3)

12 (80)

 

Day 1

    

Median SOFA*, [IQR]

8

9 [8–9.8]

9 [4.5–10.5]

0.335

Day 3–4

    

Median mHLA-DR (Ab/C), [IQR]

28,272 [18308–30940]

5098 [3544–8223]

4680 [3097–8709]

< 0.001

Median TNFα secretion post-LPS stimulation (pg/mL), [IQR]

4176 [3644–5412]

1590 [1289–2442]

719 [474–1090]

< 0.001

Outcomes

    

Hospital-acquired infections*, n (%)

0 (0)

1 (7.1)

7 (46.7)

0.035

Median ICU length of stay*, [IQR]

2

7.5 [5–9.8]

11 [7–16]

0.050

Mortality at day 28*, n (%)

0 (0)

3 (21.4)

0 (0)

0.053

  1. For categorical variables Chi-squared test was used and for numerical variables, t test (parametric) or Wilcoxon (non-parametric) was used.
  2. SOFA sequential organ failure assessment, ICU intensive care unit, HLA-DR human leukocyte antigen DR, TNFα tumour necrosis factor alpha, LPS lipopolysaccharide.
  3. *Parameters measured exclusively for septic patients.
  4. aPresence of comorbidities was affirmative when at least one of the following comorbidity was present in the patient: chronic pulmonary disease, heart failure, myocardial infarction, ulcer, diabetes, renal failure, or malign solid tumour.
Back to article page